immatics is into the discovery and development of tumor-associated peptides (TUMAPs) for the immunotherapy of cancer.
immatics’ pipeline includes IMA910 for the treatment of colorectal carcinoma which has recently entered a large Phase I/II clinical trial.
Scancell claimed that its first vaccine using its patented ImmunoBody technology is SCIB1, a new DNA vaccine being developed for the treatment of melanoma, which is currently in Phase 1 clinical trials.
In the research collaboration with immatics, colorectal cancer-specific TUMAPs are expected to be incorporated into ImmunoBody constructs to create ImmunoBody vaccines targeted towards colorectal cancer.
If the research project is successful, immatics and Scancell are expected to explore the further development of any product candidates.
Paul Higham, CEO of immatics, said: “’We are very pleased to enter this research collaboration with Scancell as the colorectal TUMAPs identified by immatics can complement and enhance Scancell’s ImmunoBody technology. We eagerly await the results.“
Professor Lindy Durrant, CEO of Scancell, said: “Our research collaboration with immatics is expected to create the opportunity to bring together two technologies.
“We will be working together with immatics to evaluate the combination of the immatics’ TUMAP technology with Scancell’s ImmunoBody technology for the development of new vaccines for the treatment of colorectal cancer.”